OVID vs PRAX
OVID: A biopharmaceutical company developing small molecule medicines targeting neuronal hyperexcitability to treat drug-resistant epilepsies, developmental epileptic encephalopathies, and psychosis. PRAX: A clinical-stage CNS biotech translating genetic epilepsy insights into precision therapies for neurological disorders via proprietary small-molecule and antisense oligonucleotide platforms.
Side-by-side fundamentals
| Metric | OVID | PRAX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.38 | $312.10 | |
| Market cap as of 2026-07-23 | $438M | $8.7B | |
| PEG as of 2026-07-23 | n/a | -0.95 | |
| Net margin as of 2026-07-23 | -240.1% | -2137.5% | OVID higher |
| Operating margin as of 2026-07-23 | -585.2% | -2340.3% | OVID higher |
| ROE as of 2026-07-23 | -22.5% | -43.0% | OVID higher |
| ROA as of 2026-07-23 | -18.7% | -40.2% | OVID higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +1199.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +69.0% | n/a | |
| Beta as of 2026-07-23 | 0.26 | 2.80 | |
| 1-year return as of 2026-07-22 close | +255.8% | +476.3% | PRAX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.